» Articles » PMID: 39906027

Moving Away from Metal: Step Toward the Future with Bioresorbable Vascular Scaffolds and Novel Antiproliferative Agents

Overview
Journal JVS Vasc Sci
Date 2025 Feb 5
PMID 39906027
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Peripheral arterial disease (PAD) is a common source of morbidity and mortality globally and is expected to raise increase in prevalence. Many endovascular techniques exist to manage PAD; however, there remains room for improvement, especially as it relates to below-the-knee vessels. Recent evidence and devices are leading to a resurgence of interest in bioresorbable vascular scaffolds and the -limus family of antiproliferative drugs in the PAD treatment space.

Methods: This nonsystematic review examines emerging technology for treatment of PAD with a specific focus on below-the-knee vessels and bioresorbable vascular scaffolds. Additional emerging and early technology such as novel delivery platforms are also briefly discussed with directions of future research highlighted.

Results: Bioresorbable vascular scaffold biomechanics and history are highlighted. Foundational knowledge of antiproliferative agents and evolving agents in peripheral vascular disease are also described.

Conclusions: Bioresorbable vascular scaffolds are an additional endovascular tool for the treatment of peripheral vascular disease. The integration with an antiproliferative agent may result in improved patency and performance; however, there is a paucity of data in the literature at present.

References
1.
McDonald A, Iruela-Arispe M . Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury. Vascul Pharmacol. 2015; 72:9-15. PMC: 4547868. DOI: 10.1016/j.vph.2015.06.007. View

2.
Yin J, Li Y, Chen Y, Wang C, Song X . Biodegradable polymer everolimus-eluting stents versus contemporary drug-eluting stents: a systematic review and meta‑analysis. Sci Rep. 2023; 13(1):1715. PMC: 9889391. DOI: 10.1038/s41598-022-26654-5. View

3.
Shavelle D, Desai A, Abraham W, Bourge R, Raval N, Rathman L . Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study. Circ Heart Fail. 2020; 13(8):e006863. PMC: 7434214. DOI: 10.1161/CIRCHEARTFAILURE.119.006863. View

4.
Mahmoud A, Barakat A, Elgendy A, Schneibel E, Mentias A, Abuzaid A . Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv. 2017; 10(5). DOI: 10.1161/CIRCINTERVENTIONS.117.005286. View

5.
Rykowska I, Nowak I, Nowak R . Drug-Eluting Stents and Balloons-Materials, Structure Designs, and Coating Techniques: A Review. Molecules. 2020; 25(20). PMC: 7594099. DOI: 10.3390/molecules25204624. View